Abstract PS4-07-10: The Relationship Between Tumor-Infiltrating Lymphocytes (TILs), Pathologic Complete Response, and Event-Free Survival in Patients with Early-Stage Triple-Negative Breast Cancer Treated with KEYNOTE-522 regimen in a Real-World Scenario

Clinical Cancer Research 2026

View at publisher
Authors: R. Colombo Bonadio, M. C. Tavares, Flávia Cavalcanti Balint, G. Ferreira, Carlos Henrique dos Anjos, Débora De Melo Gagliato, M. L. de Brito, Daniele Xavier Assad, Daniela D. Rosa, N. J. Gomes, N. C. Nunes, Laura Testa
+22 more M. Rigesti, V. Baro, I. M. de Sousa, M. O. Andrade, M. C. Gouveia, Fernanda Madasi, José Bines, R. P. Ferreira, Candice Lima Santos, M. C. Tavares, M. F. Monteiro, Z. S. de Souza, A. U. Gomes, Bruna Migliavacca Zucchetti, Augusto Ferrari, M. F. Monteiro, Poliana Albuquerque Signorini, A. Aguilar, S. Moraes Sanches, P. G. Hoff, Maria Del Pilar Estevez-Diz, Romualdo Barroso‐Sousa
DOI: 10.1158/1557-3265.sabcs25-ps4-07-10
Cited by: 0

Abstract

Abstract Background: Tumor-infiltrating lymphocytes (TILs) are established prognostic and predictive biomarkers in early-stage triple-negative breast cancer (eTNBC). The addition of pembrolizumab to neoadjuvant chemotherapy (NAC) has demonstrated improved outcomes in this setting (KEYNOTE-522 trial). The role of TIL levels in this context needs to be further explored. Methods: The Neo-Real / GBECAM-0123 study is a retrospective multicenter cohort including patients (pts) with stage II-III TNBC treated with pembrolizumab plus NAC across institutions in Brazil and Argentina since 2020. Baseline stromal TILs were assessed on pre-treatment biopsies according to international guidelines and categorized as

Fields of Study & Subjects

Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers Breast Lesions and Carcinomas

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS4–07
Publication date
17 February 2026
Language
EN